*  Institute of Cancer Research Repository - Metastatic seminoma treated with either single agent carboplatin or cisplatin-based...
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials To study the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two randomised trials. In subgroup analyses in patients with different disease characteristics, the outcome treated with either single agent carboplatin or cisplatin-based combination chemotherapy was compared. Individual patient data from two randomised European trials involving patients with metastatic seminoma were gathered. The primary endpoint for all analyses was progression-free survival. The source data of 361 patients, 184 treated with cisplatin-based combinations and 177 treated with carboplatin single agent therapy, were entered into the analysis. Patient characteristics were comparable among the cisplatin-based and the carboplatin single agent treated patient groups with lymph ...
*  TCam-2 Seminoma Cells Exposed to Egg-Derived Microenvironment Modify Their Shape, Adhesive Pattern and Migratory Behaviour: A...
Seminoma is one of the most common Testicular Germ Cell Tumours that originates during embryonic development due to an alteration of the local niche that in turn results in a delayed or blocked differentiation of Primordial Germ Cells. The block of differentiation is actually a common way to develop cancer disease as postulated by the 'embryonic rest theory of cancer'. In agreement with this theory different studies have demonstrated that embryonic cues display the capacity of reprogramming aggressive cancer cells towards a less aggressive phenotype. Herein we investigate the ability of a culture medium added with 10% egg albumen (EW, Egg White) to modulate seminoma cell phenotype and behaviour, by ensuring a proper set of morphogenetic signals. We chose to use the TCam-2 seminoma cell line that has been established as the only available cell line, obtained from a primary testicular seminoma. EW is able to: 1) modify TCam-2 cell spreading ...
*  Institute of Cancer Research Repository - Genomic and expression profiling of human spermatocytic seminomas: Primary...
Genomic and expression profiling of human spermatocytic seminomas: Primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene Spermatocytic seminomas are solid tumors found solely in the testis of predominantly elderly individuals. We investigated these tumors using a genome-wide analysis for structural and numerical chromosomal changes through conventional karyotyping, spectral karyotyping, and array comparative genomic hybridization using a 32 K genomic tiling-path resolution BAC platform (confirmed by in situ hybridization). Our panel of five spermatocytic seminomas showed a specific pattern of chromosomal imbalances, mainly numerical in nature (range, 3-24 per tumor). Gain of chromosome 9 was the only consistent anomaly, which in one case also involved amplification of the 9p21.3-pter region. Parallel chromosome level expression profiling as well as microarray expression analyses (Affymetrix ...
*  A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic...
The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated with reduced toxicity. A total of 130 patients with advanced seminoma were randomly assigned to treatment with either single agent carboplatin (C) at a dose of 400 mg/m(2)to be corrected for glomerular filtration rate outside the range 81-120 ml min(-1)and to be administered on day 1 of a 21 day cycle to a total of 4 cycles or to etoposide + platinum (EP). The trial was designed as an equivalence study aiming to exclude a reduction in the 3-year progression-free survival in patients allocated to carboplatin of between 10 and 15%, requiring initially a target accrual of 250 patients (90% power significance level 5% (one-sided)). The trial closed after 130 patients had been randomized following recommendation by an ...
*  Surgery treatment of testicular seminoma: Costs for treatment #201531 in Germany | BookingHealth
Surgery treatment of testicular seminoma (costs for program #201531) ✔ Academic Hospital Nordwest ✔ Department of Urology and Pediatric Urology ✔ BookingHealth.com
*  Testicular seminoma | Genetic and Rare Diseases Information Center (GARD) - an NCATS Program
A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Testicular seminoma
*  Optimal Planning Target Volume for Stage I Testicular Seminoma: A Medical Research Council Randomized Trial | OncoLink
OncoLink, the Web's first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
*  Testicular Cancer: Which Treatment Should I Have for Stage I Seminoma Testicular Cancer After My Surgery? - North Kansas City...
Guides through treatment choices for stage I seminoma testicular cancer after surgery to remove the testicle. Lists reasons for and against surveillance, radiation therapy, and chemotherapy. Includes interactive tool to help you decide.
*  Seminoma Pathology: Definition, Epidemiology, Etiology
Seminoma is the most common pure germ cell tumor (GCT) of the testis, accounting for up to 50% of cases. Among mixed GCTs, seminoma is also commonly present, in which the combination of teratoma, seminoma, yolk sac tumor, and embryonal carcinoma represent about one third of mixed cases.
*  Seminoma: Stage I - UNM Comprehensive Cancer Center
It is important to understand that a few patients with Stage I seminoma already have small amounts of cancer that have spread into the lymph nodes and cannot be detected with any of the currently available tests. Undetectable areas of cancer are referred to as micrometastases. The presence of micrometastases causes cancer recurrence following treatment with surgery alone. An effective treatment is needed to cleanse the body of micrometastases in order to improve a patient's duration of survival and potential for cure. The delivery of cancer treatment following local treatment with surgery is referred to as "adjuvant" therapy and may include chemotherapy or radiation therapy.. Following surgical orchiectomy (removal of the affected testicle), approximately 15% of patients with a Stage I seminoma will experience cancer recurrence if they are not treated with additional therapy. By administering relatively low doses of chemotherapy and/or radiation therapy to the ...
*  CTV for Stage I Seminoma - Isocentre Archive
Zagars G, Pollack A: Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51:643-649, 2001 MD Anderson Practise; Red Journal Link)]. You would also agree that retrospective studies have an inherent bias and you would not give them "any importance" in terms of "evidence care medicine".. 2)The Second quoted paper suffers from similar flaws in it's assumptions. Basically it is a compiled questionnaire.. Angina-like chest pain is sometimes noncardiac in origin;to differentiate chest pain of cardiac versus noncardiac origin is impossible on the basis of history alone and up to 30% of patients presenting with such features have normal coronary arteries on angiography. The prognosis of such patients (who are often young) is good. There is often an added level of anxiety.. I am not arguing about the pattern of relapse. I am only insisting that reducing the vertebral level would not affect the heart or have any long term consequences.. I would still insist that present ...
*  Plus it
TGCTs are the most common solid tumors in young men, and their frequency is increasing (21) . The tumors are grouped in two entities, seminomas and nonseminomatous TGCTs. A few testicular malignancies are comprised of mixed seminomatous and nonseminomatous areas (22) . Seminomas, accounting for approximately half of all TGCTs, are further subdivided in two distinct subtypes. Classic seminoma is composed of fairly uniform medium-sized cells with clear cytoplasm and well-defined cell borders (22) . Human classic seminoma is supposed to originate from CIS cells. They arise early in development, resemble gonocytes, the immature germ cells, and proliferate but are unable to differentiate. Both CIS cells and classic seminomas express placental alkaline phosphatase (7 , 19, 20, 21, 22, 23) . The other variant, spermatocytic ...
*  Seminoma: Stage III
Patients with Stage III seminoma have spread of cancer outside the testes and retroperitoneal lymph nodes and are curable in more than 90% of cases.. The following is a general overview of treatment for Stage III seminoma. Cancer treatment may consist of surgery, radiation, chemotherapy, targeted therapy, or a combination of these treatment techniques. Combining two or more of these treatment techniques-called multi-modality care-has become an important approach for increasing a patient's chance of cure and prolonging survival.. In some cases, participation in a clinical trial utilizing new, innovative therapies may provide the most promising treatment. Treatments that may be available through clinical trials are discussed in the section titled Strategies to Improve Treatment.. Circumstances unique to each patient's situation influence which treatment or treatments are utilized. The potential benefits of multi-modality care, participation in a clinical trial, or standard ...
*  Bulky seminoma 4XEP experience, AFP levels - TC-Cancer.com - Testicular Cancer Information & Support Forum
Hi to all TC warriors. I found lot of useful information here since my father started fighting tc 5 months ago, and now decided to search for some advice or similar experience. Quick story: 01/10/2017 - age 64, diagnosed with pure seminoma, stage IIC. Left testicle small mass + 2 large abdominal lymph
*  Testicular cancer | Multimedia Encyclopedia | Health Information | St. Luke's Hospital
These cancers grow from germ cells, the cells that make sperm.. Seminoma: This is a slow-growing form of testicular cancer found in men in their 30s and 40s. The cancer is in the testes, but it can spread to the lymph nodes. Seminomas are very sensitive to radiation therapy.. Nonseminoma: This more common type of testicular cancer tends to grow more quickly than seminomas.. Nonseminoma tumors are often made up of more than one type of cell, and are identified according to these different cell types:. ...
*  Dictionary of Cancer Terms
Abnormal cells are found in the tiny tubules where the sperm cells begin to develop. These abnormal cells may become cancer and spread into nearby normal tissue. All tumor marker levels are normal. Also called testicular intraepithelial neoplasia and testicular intratubular germ cell neoplasia ...
*  A Nationwide Cohort Study of Surveillance for Stage I Seminoma | OncoLink
OncoLink, the Web's first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
*  Treatment of stage II seminoma
Testicular cancer is the most common solid malignancy affecting males aged 15 to 35 years, although these tumors only account for approximately 1 percent of all cancers in men. Germ cell tumors (GCTs), which account for 95 percent of testicular cance
*  Pur seminoma - surveillance or adjuvant chemo/radiotherapy? - TC-Cancer.com - Testicular Cancer Information & Support...
I have been reading threads on this forum for some time and now got histological results. I found a lump on my left testicule in the beginning of May, had a radical inguinal orchiectomy on 12th June. (translated form French, so I hope it is clear) Germinal tumour, pure seminome, intratesticular. Tumour in
*  Seminoma | OncoLink
OncoLink, the Web's first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials